Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 393

The DOI matches its Crossref record; 214 of the 214 references it cites were found in a registry or an index.

Regulated cell death pathways in kidney disease

Open access
Sanz, Ana B., Sanchez-Niño, Maria Dolores, Ramos, Adrian M., Ortiz, Alberto·2023·Nature Reviews Nephrology

Abstract

Regulated cell death through either apoptosis or necrosis contributes to parenchymal cell loss in acute and chronic kidney disease and may also modulate inflammation, fibrosis and the immune response. Therapeutic strategies that modulate apoptosis may interfere with or promote regulated necrosis. Available evidence in general supports a therapeutic benefit of targeting ferroptosis or necroptosis in preclinical models of kidney disease; however, the impact of targeting pyroptosis is less clear. The diverse forms of regulated necrosis may be interrelated, share molecular pathways and cell defence mechanisms and coexist in the same kidney disease, affecting different cell types or the same cell type synchronously or sequentially. Regulated necrosis may release damage-associated molecular patterns, which induce an inflammatory response that amplifies tissue injury (necroinflammation or immunogenic cell death). Despite some promising preclinical data, no clinical studies have targeted regulated necrosis to prevent or treat human kidney disease. Pathways of regulated cell death may contribute to the pathogenesis of various kidney diseases. Here, the authors provide an overview of the relationship between necroptosis, pyroptosis, ferroptosis and apoptosis, the evidence supporting a role for these regulated pathways of necrosis in kidney disease, strategies for therapeutic targeting and research needs. Disorders of cell number that result from an imbalance between the death of parenchymal cells and the proliferation or recruitment of maladaptive cells contributes to the pathogenesis of kidney disease. Acute kidney injury can result from an acute loss of kidney epithelial cells. In chronic kidney disease, loss of kidney epithelial cells leads to glomerulosclerosis and tubular atrophy, whereas interstitial inflammation and fibrosis result from an excess of leukocytes and myofibroblasts. Other conditions, such as acquired cystic disease and kidney cancer, are characterized by excess numbers of cyst wall and malignant cells, respectively. Cell death modalities act to clear unwanted cells, but disproportionate responses can contribute to the detrimental loss of kidney cells. Indeed, pathways of regulated cell death — including apoptosis and necrosis — have emerged as central events in the pathogenesis of various kidney diseases that may be amenable to therapeutic intervention. Modes of regulated necrosis, such as ferroptosis, necroptosis and pyroptosis may cause kidney injury directly or through the recruitment of immune cells and stimulation of inflammatory responses. Importantly, multiple layers of interconnections exist between different modalities of regulated cell death, including shared triggers, molecular components and protective mechanisms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41581-023-00694-0

Cites

214 of 214 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 214 references

Research works printed but not linked: 16

  1. Denton, M. D. et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int. 61, 2201–2209 (2002). · doi:10.1046/j.1523-1755.2002.00374.x
  2. Shah, A. et al. Acquired cystic kidney disease-associated renal cell carcinoma (ACKD-RCC) harbor recurrent mutations in KMT2C and TSC2 genes. Am. J. Surg. Pathol. 44, 1479–1486 (2020). · doi:10.1097/pas.0000000000001530
  3. Ito, H., Kasagi, N., Shomori, K., Osaki, M. & Adachi, H. Apoptosis in the human allografted kidney. Analysis by terminal deoxynucleotidyl transferase-mediated DUTP-botin nick end labeling. Transplantation 60, 794–798 (1995). · doi:10.1097/00007890-199510270-00006
  4. Lee, M. H., Choi, E. N., Jeon, Y. J. & Jung, S. C. Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy. Int. J. Mol. Med. 30, 1275–1280 (2012). · doi:10.3892/ijmm.2012.1139
  5. Olsen, S. et al. Primary acute renal failure (“acute tubular necrosis”) in the transplanted kidney: morphology and pathogenesis. Medicine 68, 173–187 (1989). · doi:10.1097/00005792-198905000-00005
  6. Cao, H. et al. Novel effects of combination therapy through inhibition of caspase-1/gasdermin D induced-pyroptosis in lupus nephritis. Front. Immunol. 12, 720877 (2021). · doi:10.3389/fimmu.2021.720877
  7. Tonnus, W. & Linkermann, A. Gasdermin D and pyroptosis in acute kidney injury. Kidney Int. 96, 1061–1063 (2019). · doi:10.1016/j.kint.2019.07.002
  8. Humanes, B. et al. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. Kidney Int. 82, 652–663 (2012). · doi:10.1038/ki.2012.199
  9. Jado, J. C. et al. Nephroprotective effect of cilastatin against gentamicin-induced renal injury in vitro and in vivo without altering its bactericidal efficiency. Antioxidants 9, 821 (2020). · doi:10.3390/antiox9090821
  10. Matsushita, K. et al. Cilastatin ameliorates rhabdomyolysis-induced AKI in mice. J. Am. Soc. Nephrol. 32, 2579–2594 (2021). · doi:10.1681/asn.2020030263
  11. Pérez, M. et al. Inhibition of brush border dipeptidase with cilastatin reduces toxic accumulation of cyclosporin A in kidney proximal tubule epithelial cells. Nephrol. Dial. Transpl. 19, 2445–2455 (2004). · doi:10.1093/ndt/gfh397
  12. Tejedor, A. et al. Cilastatin protection against cyclosporin A-induced nephrotoxicity: clinical evidence. Curr. Med. Res. Opin. 23, 505–513 (2007). · doi:10.1185/030079906x167633
  13. González-Nicolás, M., González-Guerrero, C., Pérez-Fernández, V. A. & Lázaro, A. Cilastatin: a potential treatment strategy against COVID-19 that may decrease viral replication and protect from the cytokine storm. Clin. Kidney J. 13, 903–905 (2020). · doi:10.1093/ckj/sfaa193
  14. Poterucha, T. J. & Goldhaber, S. Z. Warfarin and vascular calcification. Am. J. Med. 129, 635.e1–635.e4 (2016). · doi:10.1016/j.amjmed.2015.11.032
  15. Raizman, J. E., Colbourne, P. D., LeGatt, D. F., Chow, D. & Rudolph, L. Glistening urine sample from a patient with delirium. Clin. Chem. 63, 1306–1307 (2017). · doi:10.1373/clinchem.2017.272377
  16. National Toxicology Program.NTP toxicology and carcinogenesis studies of primidone (CAS no. 125-33-7) in F344/N rats and B6C3F1 mice (feed studies). Natl Toxicol. Program. Tech. Rep. Ser. 476, 1–290 (2000).

Cited by

See all 393

Metadata

Authors
Sanz, A. B., Sanchez-Niño, M. D., Ramos, A. M., & Ortiz, A.
Venue
Nature Reviews Nephrology
Published
2023-03-23
Volume
19
Issue
5
Pages
281-299
ISSN
  • 1745-8323 (ISSN-L)
  • 1759-5061
  • 1759-507X
OpenAlex
W4360612283
Cited by
393
References
214
FWCI
9.80
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Regulated cell death pathways in kidney disease. https://app.cochat.ai/papers/10.1038/s41581-023-00694-0
The paper
Sanz, A. B., Sanchez-Niño, M. D., Ramos, A. M., & Ortiz, A. (2023). Regulated cell death pathways in kidney disease. Nature Reviews Nephrology. https://doi.org/10.1038/s41581-023-00694-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.